Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Steve Gillis
AddedMar 31, 2024
UpdatedMay 31, 2026
Steve Gillis

Steve Gillis

Board Member, Takeda

Crunchbase

Steve Gillis's Career

Takeda
Takeda

San Diego, CA, US

Board Member· Board
Accelerator
Accelerator

Seattle, WA, US

Board Member· Board
Vlst
Vlst

Seattle, WA, US

Board Member· Board
Nohla Therapeutics
Nohla Therapeutics

Seattle, WA, US

Board Member· Board
Theraclone Sciences
Theraclone Sciences

Seattle, WA, US

Board Member· Board
HiberCell
HiberCell

New York City, NY, US

Board Member· Board
OncoResponse
OncoResponse

Seattle, WA, US

Board Member· Board
eGenesis
eGenesis

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Steve Gillis's Career

Takeda
Takeda
Public$57.8M47.3k1781San Diego, CA, US
Board Member· Board

Leadership at Takeda

Andrew PlumpAndrew PlumpBoard Member
Masato IwasakiMasato IwasakiBoard Member
Yasuhiko YamanakaYasuhiko YamanakaBoard Member
Masahiro SakaneMasahiro SakaneBoard Member
Masami IijimaMasami IijimaBoard Member
Yasuchika HasegawaYasuchika HasegawaBoard Member
Accelerator
Accelerator
Investment FirmInvestment Firm$50.5M52003Seattle, WA, US
Board Member· Board

Leadership at Accelerator

Asish K. XavierAsish K. XavierBoard Member
Chad WaiteChad WaiteBoard Member
Joel S. MarcusJoel S. MarcusBoard Member
Barbara DaltonBarbara DaltonBoard Member
Tachi YamadaTachi YamadaBoard Member
Lee HoodLee HoodBoard Member
Vlst
Vlst
Public$55M302004Seattle, WA, US
Board Member· Board

Leadership at Vlst

Heather PrestonHeather PrestonBoard Member
Gerry LangelerGerry LangelerBoard Member
Martin SimonettiMartin SimonettiBoard Member
Gregory SesslerGregory SesslerBoard Member
Craig SmithCraig SmithBoard Member

Similar to Vlst

VirxsysVirxsysGaithersburg, MD, USTherapiesest. 1998VirxsysGaithersburg, MD, US · est. 1998

VIRxSYS Corp, a private biotech firm, innovates therapies for serious human diseases.

Pre-Seed · $102.9M30
ViriomViriomSan Diego, CA, USHBV Treatments, HIV Treatmentsest. 2009ViriomSan Diego, CA, US · est. 2009

Viriom: A therapeutic biotech firm innovating treatments for HIV and Hepatitis B.

Series B · $35.4M200
Logical TherapeuticsLogical TherapeuticsWaltham, MA, USBiopharmaceuticalsest. 2005Logical TherapeuticsWaltham, MA, US · est. 2005

Logical Therapeutics, Inc.: A U.S. biopharmaceutical firm developing drugs for inflammation-related diseases.

Public · $79.4M30
VLP TherapeuticsVLP TherapeuticsGaithersburg, MD, USAntibody Agents, Vaccinesest. 2012VLP TherapeuticsGaithersburg, MD, US · est. 2012

US-based VLP Therapeutics develops vaccines and targeted antibody agents for cancer and infectious diseases.

Series A · $43.3M7
Nohla Therapeutics
Nohla Therapeutics
Acquired$120.5M02015Seattle, WA, US
Board Member· Board

Leadership at Nohla Therapeutics

Brian DanielsBrian DanielsBoard Member
Colleen DelaneyColleen DelaneyFounder
Michael SistenichMichael SistenichBoard Member
Kathleen FanningKathleen FanningBoard Member
Lawrence Bernard GozlanLawrence Bernard GozlanBoard Member
Theraclone Sciences
Theraclone Sciences
Seed$63.2M322004Seattle, WA, US
Board Member· Board

Leadership at Theraclone Sciences

Wende HuttonWende HuttonBoard Member
Chris MirabelliChris MirabelliBoard Member
Johnny StineJohnny StineFounder
HiberCell
HiberCell
Series C$158.2M872019New York City, NY, US
Board Member· Board

Leadership at HiberCell

Ari NowacekAri NowacekCo-Founder
Colin GoddardColin GoddardBoard Member
Alan RigbyAlan RigbyCo-Founder
Jonathan LanfearJonathan LanfearCEO
Julio Aguirre-GhisoJulio Aguirre-GhisoCo-Founder
Cindy JacobsCindy JacobsBoard Member

Similar to HiberCell

HebeCellHebeCellNatick, MA, USCell Therapiesest. 2016HebeCellNatick, MA, US · est. 2016

MA-based HebeCell pioneers in immuno-oncology and regenerative medicine through cell-based therapeutics.

Series A · $63M24
CellvieCellvieHouston, TX, USMitochondria Therapiesest. 2018CellvieHouston, TX, US · est. 2018

Cellvie: Developing cell-derived medicines by leveraging the therapeutic potential of mitochondria to treat ischemia-reperfusion injuries.

Seed · $10.5M9
HibernaidHibernaidTroy, NY, USMedical Therapiesest. 2011HibernaidTroy, NY, US · est. 2011

Hibernaid: A private firm developing unique acute medical therapies for high-risk critical care patients.

Angel · $100k5
Cellevolve BioCellevolve BioSan Francisco, CA, USCell Therapyest. 2020Cellevolve BioSan Francisco, CA, US · est. 2020

San Francisco-based cell therapy provider, partnering with global innovators to advance and commercialize novel therapeutics.

Seed · $6M9
OncoResponse
OncoResponse
Series B$130.1M202016Seattle, WA, US
Board Member· Board

Leadership at OncoResponse

John McKearnJohn McKearnBoard Member
Clifford StocksClifford StocksFounder
Andrew PerlmanAndrew PerlmanBoard Member
Sean A. McCarthySean A. McCarthyBoard Member
Roberto De PontiRoberto De PontiBoard Member
Patrick HojloPatrick HojloBoard Member
eGenesis
eGenesis
Series C$265M1052015Cambridge, MA, US
Board Member· Board

Leadership at eGenesis

Isaac CiechanoverIsaac CiechanoverBoard Member
Bob MoreBob MoreBoard Member
Al WiegmanAl WiegmanBoard Member
Boris NikolicBoris NikolicBoard Member
Mike CurtisMike CurtisCEO
Daniel LynchDaniel LynchBoard Member

Similar to eGenesis

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
InGeneronInGeneronHouston, TX, USRegenerative Therapiesest. 2006InGeneronHouston, TX, US · est. 2006

InGeneron: A multinational biotech firm unlocking patient healing through innovative regenerative therapies.

Series D · $51M32
ExogenesisExogenesisBillerica, MA, USMedical Devicesest. 2005ExogenesisBillerica, MA, US · est. 2005

Exogenesis Corp., based in Billerica, US, develops and processes implantable medical devices.

Seed · $7.8M17
InscriptaInscriptaBoulder, CO, USGenome Engineeringest. 2015InscriptaBoulder, CO, US · est. 2015

Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.

Series A · $463.9M178

Steve Gillis's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Steve Gillis

William HearlWilliam HearlBoard Member · BioHealth InnovationEric FurfineEric FurfineBoard Member · ImmuneXciteJim BarlowJim BarlowCEO · ImmunoGenesisPhilip WagenheimPhilip WagenheimBoard Member · ImmunomeBahija JallalBahija JallalBoard Member · Outpace BioSteven JamesSteven JamesBoard Member · Armetheon